CANC holdings
Tema Oncology ETF
Positions
57 stored of 57 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc | US76155X1000 | 76155X100 | 7.729% | $13.6M | Equity (common) | Corporate | United States | USD |
| 2 | Eli Lilly & Co | US5324571083 | 532457108 | 4.820% | $8.5M | Equity (common) | Corporate | United States | USD |
| 3 | Roche Holding AG | US7711951043 | 771195104 | 4.214% | $7.4M | Equity (common) | Corporate | Switzerland | USD |
| 4 | Cogent Biosciences Inc | US19240Q2012 | 19240Q201 | 4.097% | $7.2M | Equity (common) | Corporate | United States | USD |
| 5 | Novartis AG | CH0012005267 | Not reported | 4.029% | $7.1M | Equity (common) | Corporate | Switzerland | CHF |
| 6 | Immunome Inc | US45257U1088 | 45257U108 | 3.912% | $6.9M | Equity (common) | Corporate | United States | USD |
| 7 | Celcuity Inc | US15102K1007 | 15102K100 | 3.580% | $6.3M | Equity (common) | Corporate | United States | USD |
| 8 | Merck & Co Inc | US58933Y1055 | 58933Y105 | 3.571% | $6.3M | Equity (common) | Corporate | United States | USD |
| 9 | AstraZeneca PLC | GB0009895292 | Not reported | 3.535% | $6.2M | Equity (common) | Corporate | United Kingdom | GBP |
| 10 | Nuvalent Inc | US6707031075 | 670703107 | 3.369% | $5.9M | Equity (common) | Corporate | United States | USD |
| 11 | Bristol-Myers Squibb Co | US1101221083 | 110122108 | 3.301% | $5.8M | Equity (common) | Corporate | United States | USD |
| 12 | Legend Biotech Corp | US52490G1022 | 52490G102 | 2.993% | $5.3M | Equity (common) | Corporate | United States | USD |
| 13 | AbbVie Inc | US00287Y1091 | 00287Y109 | 2.806% | $4.9M | Equity (common) | Corporate | United States | USD |
| 14 | Exelixis Inc | US30161Q1040 | 30161Q104 | 2.777% | $4.9M | Equity (common) | Corporate | United States | USD |
| 15 | Bridgebio Pharma Inc | US10806X1028 | 10806X102 | 2.753% | $4.8M | Equity (common) | Corporate | United States | USD |
| 16 | Johnson & Johnson | US4781601046 | 478160104 | 2.546% | $4.5M | Equity (common) | Corporate | United States | USD |
| 17 | CG oncology Inc | US1569441009 | 156944100 | 2.430% | $4.3M | Equity (common) | Corporate | United States | USD |
| 18 | Genmab A/S | US3723032062 | 372303206 | 2.375% | $4.2M | Equity (common) | Corporate | Denmark | USD |
| 19 | Ideaya Biosciences Inc | US45166A1025 | 45166A102 | 2.273% | $4.0M | Equity (common) | Corporate | United States | USD |
| 20 | Amgen Inc | US0311621009 | 031162100 | 2.107% | $3.7M | Equity (common) | Corporate | United States | USD |
| 21 | Zai Lab Ltd | US98887Q1040 | 98887Q104 | 1.978% | $3.5M | Equity (common) | Corporate | China | USD |
| 22 | BeOne Medicines Ltd | US07725L1026 | 07725L102 | 1.881% | $3.3M | Equity (common) | Corporate | United States | USD |
| 23 | Zymeworks Inc | US98985Y1082 | 98985Y108 | 1.507% | $2.7M | Equity (common) | Corporate | United States | USD |
| 24 | Enliven Therapeutics Inc | US29337E1029 | 29337E102 | 1.307% | $2.3M | Equity (common) | Corporate | United States | USD |
| 25 | Relay Therapeutics Inc | US75943R1023 | 75943R102 | 1.285% | $2.3M | Equity (common) | Corporate | United States | USD |
| 26 | Halozyme Therapeutics Inc | US40637H1095 | 40637H109 | 1.231% | $2.2M | Equity (common) | Corporate | United States | USD |
| 27 | Summit Therapeutics Inc | US86627T1088 | 86627T108 | 1.206% | $2.1M | Equity (common) | Corporate | United States | USD |
| 28 | Arcus Biosciences Inc | US03969F1093 | 03969F109 | 1.196% | $2.1M | Equity (common) | Corporate | United States | USD |
| 29 | Gilead Sciences Inc | US3755581036 | 375558103 | 1.121% | $2.0M | Equity (common) | Corporate | United States | USD |
| 30 | Immatics NV | NL0015285941 | Not reported | 1.121% | $2.0M | Equity (common) | Corporate | Germany | USD |
| 31 | First American Treasury Obliga First American Treasury Obligations Fund | US31846V3289 | 31846V328 | 1.090% | $1.9M | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |
| 32 | Erasca Inc | US29479A1088 | 29479A108 | 1.078% | $1.9M | Equity (common) | Corporate | United States | USD |
| 33 | Nuvation Bio Inc | US67080N1019 | 67080N101 | 1.073% | $1.9M | Equity (common) | Corporate | United States | USD |
| 34 | AnaptysBio Inc | US0327241065 | 032724106 | 0.988% | $1.7M | Equity (common) | Corporate | United States | USD |
| 35 | UroGen Pharma Ltd | IL0011407140 | Not reported | 0.935% | $1.6M | Equity (common) | Corporate | United States | USD |
| 36 | Guardant Health Inc | US40131M1099 | 40131M109 | 0.809% | $1.4M | Equity (common) | Corporate | United States | USD |
| 37 | Syndax Pharmaceuticals Inc | US87164F1057 | 87164F105 | 0.803% | $1.4M | Equity (common) | Corporate | United States | USD |
| 38 | Corvus Pharmaceuticals Inc | US2210151005 | 221015100 | 0.764% | $1.3M | Equity (common) | Corporate | United States | USD |
| 39 | Regeneron Pharmaceuticals Inc | US75886F1075 | 75886F107 | 0.746% | $1.3M | Equity (common) | Corporate | United States | USD |
| 40 | ArriVent Biopharma Inc | US04272N1028 | 04272N102 | 0.735% | $1.3M | Equity (common) | Corporate | United States | USD |
| 41 | Chugai Pharmaceutical Co Ltd | JP3519400000 | Not reported | 0.667% | $1.2M | Equity (common) | Corporate | Japan | JPY |
| 42 | Iovance Biotherapeutics Inc | US4622601007 | 462260100 | 0.652% | $1.1M | Equity (common) | Corporate | United States | USD |
| 43 | Inhibrx Biosciences Inc | US45720N1037 | 45720N103 | 0.601% | $1.1M | Equity (common) | Corporate | United States | USD |
| 44 | Olema Pharmaceuticals Inc | US68062P1066 | 68062P106 | 0.597% | $1.1M | Equity (common) | Corporate | United States | USD |
| 45 | Cullinan Therapeutics Inc | US2300311063 | 230031106 | 0.586% | $1.0M | Equity (common) | Corporate | United States | USD |
| 46 | Natera Inc | US6323071042 | 632307104 | 0.537% | $947K | Equity (common) | Corporate | United States | USD |
| 47 | First Tracks Biotherapeutics I First Tracks Biotherapeutics Inc | US3371851029 | 337185102 | 0.529% | $932K | Equity (common) | Corporate | United States | USD |
| 48 | Immunocore Holdings PLC | US45258D1054 | 45258D105 | 0.506% | $891K | Equity (common) | Corporate | United Kingdom | USD |
| 49 | BridgeBio Oncology Therapeutic BridgeBio Oncology Therapeutics Inc | US1079241022 | 107924102 | 0.475% | $837K | Equity (common) | Corporate | United States | USD |
| 50 | CytomX Therapeutics Inc | US23284F1057 | 23284F105 | 0.468% | $824K | Equity (common) | Corporate | United States | USD |
| 51 | HUTCHMED China Ltd | US44842L1035 | 44842L103 | 0.441% | $777K | Equity (common) | Corporate | Hong Kong | USD |
| 52 | Arvinas Inc | US04335A1051 | 04335A105 | 0.429% | $755K | Equity (common) | Corporate | United States | USD |
| 53 | Janux Therapeutics Inc | US47103J1051 | 47103J105 | 0.427% | $752K | Equity (common) | Corporate | United States | USD |
| 54 | Adlai Nortye Ltd | US00704R1095 | 00704R109 | 0.301% | $530K | Equity (common) | Corporate | Cayman Islands | USD |
| 55 | Tyra Biosciences Inc | US90240B1061 | 90240B106 | 0.299% | $527K | Equity (common) | Corporate | United States | USD |
| 56 | ORIC Pharmaceuticals Inc | US68622P1093 | 68622P109 | 0.278% | $490K | Equity (common) | Corporate | United States | USD |
| 57 | SELLAS Life Sciences Group Inc | US81642T2096 | 81642T209 | 0.215% | $379K | Equity (common) | Corporate | United States | USD |